Feedback
Settings

Settings

Goto Application

1. WO2021064188 - COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT

Submit observation
PermaLink
Publication Number WO/2021/064188
Publication Date 08.04.2021
International Application No. PCT/EP2020/077686
International Filing Date 02.10.2020
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 31/497 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965Non-condensed pyrazines
497containing further heterocyclic rings
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants
  • 4SC AG [DE]/[DE]
Inventors
  • HAMM, Svetlana
  • HERMANN, Frank
Agents
  • BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB
Priority Data
19201152.602.10.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT
(FR) COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE CTLA-4 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER
front page image
Abstract
(EN)
The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with CTLA-4 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for the treatment of cancer. (Formula)
(FR)
L'invention concerne des utilisations médicales d'un inhibiteur de HDAC de formule générale I, où R1 à R7 sont tels que décrits dans la description, ou un sel ou solvate de celui-ci en combinaison avec un inhibiteur de CTLA-4 et un inhibiteur de PD-1 ou un inhibiteur de PD-L1 pour le traitement du cancer. (Formule)
Latest bibliographic data on file with the International Bureau
# -